CYCLACEL®

*Improving patient lives*
*with innovative medicines based on cancer biology*

www.cyclacel.com; NASDAQ: CYCC (common), CYCCP (preferred)

Cyclacel is a biopharmaceutical company developing innovative medicines that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Cyclacel is an oncology pioneer with a vision to improve patient healthcare by translating insights in cell cycle biology in cancer into medicines. The Company's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates. Cyclacel retains virtually all worldwide marketing rights to its compounds.

## A PIONEER IN CELL CYCLE BIOLOGY

Applying its core strength in cell cycle biology, Cyclacel is advancing a pipeline of small molecule drugs designed to stop uncontrolled cell division including three clinical stage compounds. The Company's founder, Professor Sir David Lane, is a leading authority in cell cycle biology credited with the discovery of p53, one of the most commonly mutated tumor suppressor genes in patients with cancer. Cyclacel's first Chief Scientist, Professor David Glover, is a recognized leader in mitosis biology and discoverer of the aurora and polo mitotic kinase families, which are essential cell cycle control mechanisms that regulate cancer cell division.

## FINANCIAL HIGHLIGHTS (as of September 30, 2018)

- Cash and Equivalents (Q3 '18): $19.0 million
- Est. 2018 operating cash burn ~$10.9 million
- Est. funding to Q2 '20
- Common Shares Outstanding: 12.0 million

## 2018 KEY COMPANY HIGHLIGHTS

- Announced a 3-year strategic alliance agreement with MD Anderson Cancer Center
- Opened for enrollment CYC065 Phase 1b in R/R CLL patients in combination with venetoclax
- First patient dosed in Phase 1b/2 IST of sapacitabine and olaparib combination in BRCA mutant breast cancer patients
- Activated first-in-human study for CYC140 PLK1 inhibitor
- Sapacitabine and seliciclib combination – Update data from BRCA positive advanced breast, ovarian and pancreatic cancer patients
- Completed meetings with 3 European regulatory authorities regarding sapacitabine in elderly AML
- Appointed Robert J. Spiegel, M.D. to the Board of Directors





## ANALYST COVERAGE

**Andrew S. Fein,** *H.C. Wainwright*
afein@hcwresearch.com
**Jotin Marango,** *ROTH Capital Ptnrs.*
jmarango@roth.com
**Wangzhi Li,** *Ladenburg Thalmann*
wli@ladenburg.com

## INVESTOR/MEDIA CONTACTS

**Paul McBarron**
pmcbarron@cyclacel.com
**Alex Fudukidis**
alex.fudukidis@russopartnersllc.com

## CYC065 CLINICAL PROGRESS

### Small molecule targeting cyclin-dependent kinases CDK2 & CDK9

**Phase 1 CYC065 data highlight potential best-in-class Mcl-1 suppression.** Prolonged reduction of Mcl-1 expression (>24 hours) was observed in 11 out of 13 patients treated at the recommended Phase 2 dose (RP2D) as reported at AACR 2018. Anticancer activity observed in 6 patients treated with a single dose of CYC065.

**CYC065 could help overcome resistance to available cancer treatment by suppressing pro-survival proteins.** Preclinical data of a CYC065-venetoclax combination reported at AACR 2018 showed activity in CLL samples which were resistant to either agent alone. These findings support the hypothesis that dual targeting of Mcl-1- and Bcl-2-dependent mechanisms could induce synergistic cell death. We anticipate other mechanistically-led opportunities to address treatment resistance caused by amplification of Mcl-1, MYC or Cyclin E in various cancers, including acquired resistance to approved CDK4/6 inhibitors in ER +ve, HER2 -ve breast cancer.

## CYC140 CLINICAL PROGRESS

Internally discovered, Polo-like-kinase 1 (PLK1) inhibitor. A first-in-human study has been activated and is open for enrollment of patients with advanced leukemias. CYC140 has promising preclinical activity also in solid tumors.

### MANAGEMENT

Spiro Rombotis
*President & Chief Executive Officer*
Paul McBarron
*EVP, Finance & Chief Operating Officer*
Judy Chiao, MD
*Vice President, Clinical Development & Regulatory* Affairs
Amartya Basu, PhD
*Senior Director, Project Mgmt. & Business Development*

### CONTACT DETAILS


Cyclacel Pharmaceuticals, Inc.
200 Connell Drive, # 1500
Berkeley Heights, NJ 07922
Tel: +1 (908) 517 7330
Email: ir@cyclacel.com

Cyclacel Ltd
1 James Lindsay Place
Dundee, Scotland
DD1 5JJ, U.K.
Tel: +44 (1382) 206 062


## SAPACITABINE CLINICAL PROGRESS

### Oral pro-drug with unique DNA damage response (DDR) mechanism

**BRCA +ve solid tumors:** Data presented at ASCO 2016 with an all-oral combination of sapacitabine and seliciclib (Cyclacel CDKi) showed durable clinical benefit (PRs & prolonged SD) in BRCA +ve patients with breast, ovarian and pancreatic cancers. A Phase 1b/2 IST in combination with the PARP inhibitor olaparib has started enrollment in BRCA mutant patients with breast cancer.

**Sapacitabine in AML:** Completed meetings with three EU national regulatory authorities to discuss data from Phase 3 study of sapacitabine in elderly patients with AML. Evaluating potential request for scientific advice.

## MD ANDERSON – CYCLACEL ALLIANCE

This three-year strategic alliance with MD Anderson will enable evaluation of CYC065, CYC140 and sapacitabine either as single agents or in combination with approved drugs in four clinical studies enrolling up to 170 patients in total. The collaboration leverages MD Anderson's expertise in development of drugs for hematological malignancies and Cyclacel's novel drug portfolio and knowledge of cell cycle biology and mechanisms of cancer cell resistance.